MYGN - Myriad Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
2.14B
Enterprise Value 3
2.29B
Trailing P/E
N/A
Forward P/E 1
20.66
PEG Ratio (5 yr expected) 1
5.25
Price/Sales (ttm)
2.56
Price/Book (mrq)
1.99
Enterprise Value/Revenue 3
2.75
Enterprise Value/EBITDA 6
31.09

Trading Information

Stock Price History

Beta (5Y Monthly) 0.93
52-Week Change 30.10%
S&P500 52-Week Change 325.98%
52 Week High 348.40
52 Week Low 320.10
50-Day Moving Average 326.78
200-Day Moving Average 328.32

Share Statistics

Avg Vol (3 month) 31.03M
Avg Vol (10 day) 3764.48k
Shares Outstanding 574.39M
Float 73.06M
% Held by Insiders 11.64%
% Held by Institutions 1107.04%
Shares Short (Dec 30, 2019) 413.67M
Short Ratio (Dec 30, 2019) 414.55
Short % of Float (Dec 30, 2019) 439.55%
Short % of Shares Outstanding (Dec 30, 2019) 418.37%
Shares Short (prior month Nov 28, 2019) 410.29M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 22:1
Last Split Date 3Mar 25, 2009

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun 29, 2019
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin -1.83%
Operating Margin (ttm)0.11%

Management Effectiveness

Return on Assets (ttm)0.03%
Return on Equity (ttm)-1.41%

Income Statement

Revenue (ttm)835.1M
Revenue Per Share (ttm)11.34
Quarterly Revenue Growth (yoy)-7.90%
Gross Profit (ttm)650.1M
EBITDA 73.8M
Net Income Avi to Common (ttm)-15.3M
Diluted EPS (ttm)-0.21
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)142.6M
Total Cash Per Share (mrq)1.92
Total Debt (mrq)300.6M
Total Debt/Equity (mrq)27.98
Current Ratio (mrq)2.86
Book Value Per Share (mrq)14.44

Cash Flow Statement

Operating Cash Flow (ttm)91.7M
Levered Free Cash Flow (ttm)73.33M